Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Panther Therapeutics is a Cambridge, MA-based biotechnology company focused on developing the next generation of targeted cancer therapies. Leveraging its proprietary Sagittari™ platform, Panther designs and develops tumor-restricted therapeutics, such as antibody-drug conjugates (ADCs) and STING agonists, that are engineered to be preferentially activated within the tumor microenvironment. This approach aims to maximize efficacy against cancer cells while minimizing systemic toxicity and improving the therapeutic window for potent anti-cancer agents. Their lead programs target challenging oncology indications with high unmet medical needs.
Core research and development activities, including discovery, preclinical studies, and formulation for its oncology pipeline. Also serves as the center for strategic planning, business development, and corporate operations.
Operates within LabCentral, a premier shared laboratory and co-working space for life-science startups, offering access to advanced research equipment, operational support, and a vibrant entrepreneurial ecosystem.
A fast-paced, innovative, and highly collaborative environment focused on scientific excellence and translating research into impactful cancer therapies. Emphasis on teamwork and entrepreneurial spirit within the supportive LabCentral community.
Its Cambridge location places Panther Therapeutics in the heart of one of the world's leading biotechnology clusters, providing unparalleled access to talent, academic collaborations, investors, and industry partners crucial for growth and innovation in oncology.
Panther Therapeutics is primarily based in the United States. While its direct physical presence is concentrated at its Cambridge headquarters, the company's mission to develop impactful cancer therapies has global implications. As its drug candidates progress, Panther Therapeutics may engage in international clinical trials, collaborations with global research institutions, and partnerships with pharmaceutical companies worldwide to bring its innovations to patients globally. Currently, specific international office locations are not publicly listed.
c/o LabCentral, 700 Main Street North
Cambridge
MA
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, PanTher Therapeutics' leadership includes:
PanTher Therapeutics has been backed by several prominent investors over the years, including:
Based on publicly available information, there have been no major C-suite or VP-level executive hires or departures announced by Panther Therapeutics in the last 12 months. The current leadership team appears focused on advancing the company's pipeline following its Series A financing.
Discover the tools PanTher Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Panther Therapeutics likely utilizes standard corporate email formats based on employee names and their company domain, panthertx.com. A common pattern for technology and biotech companies is the first initial followed by the last name.
[first_initial][last]@panthertx.com
Format
tbombas@panthertx.com
Example
70%
Success rate
Panther Therapeutics Website / Business Wire • April 5, 2024
Panther Therapeutics announced its upcoming presentation of preclinical data for PTM-001, its STING agonist antibody-drug conjugate (ADC) product candidate, at the American Association for Cancer Research (AACR) Annual Meeting 2024. The presentation will also highlight the company's Sagittari™ targeted delivery platform....more
PR Newswire • May 2, 2023
Panther Therapeutics officially launched with the announcement of a $52 million Series A financing. The funding was co-led by Sofinnova Partners and Abingworth, with significant participation from Roche Venture Fund, Schmidt Futures, and others. These funds are designated to advance Panther's pipeline of tumor-targeted therapeutics, developed using its proprietary Sagittari™ platform....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including PanTher Therapeutics, are just a search away.